Review paper. Gluten-related disorders and schizophrenia - potential linking mechanisms, diagnostic and therapeutic challenge

Open access

Abstract

More and more evidence confirms the theory that the intake of cereal products containing gluten may play an important role in the pathogenesis of many diseases. There are also premises indicating the relationship between the so-called gluten-related diseases and the development and course of mental disorders, including schizophrenia.

The aim of this article is to review the literature on the potential relationship between the consumption of gluten and schizophrenia, considering the etiopathogenesis and the role of gluten-free diet in the treatment of schizophrenia.

Methods: There were analysed available research papers in PubMed and Google Scholar with the key words: schizophrenia, gluten- related disorders, allergy to grain products, celiac disease, microbiota, immune system, exorphins and time span: 1960-2016 .

Conclusions: Existing research results indicate a possible relationship between diet rich in grain products with high gluten content and the occurrence or exacerbation of schizophrenia symptoms. However, further studies are necessary to: 1) identify groups of patients for whom the consumption of cereal products (gluten) is associated with a particular risk of schizophrenia exacerbation, 2) determine the mechanisms relating the consumption of gluten with the mental state of schizophrenic patients, 3) get the possible benefits of implementing gluten-free diet in patients with schizophrenia.

1. Tovoli F., Masi C., Guidetti E., Negrini G., Paterini P., Bolondi L.. Clinical and diagnostic aspects of gluten related disorders. World J Clin Cases. 2015;3(3):275-84.

2. Sapone A., Bai J. C., Ciacci C., Dolinsek J., Green P.H.R., Hadjivassiliou, et al. Spectrum of gluten-related disorders: Consensus on new nomenclature and classification. BMC Med. 2012;10:13.

3. Fasano A., Catassi C. Celiac disease. N Eng J of Med. 2012; 367(25): 2419-2426.

4. Jackson Allen PL.. Guidelines for the diagnosis and treatment of celiac disease in children. Pediatr Nurs. 2004; 30(6): 473-476.

5. Catassi C, Gobellis G. Coeliac disease epidemiology is alive and kicking, especially in the developing world. Dig Liver Dis. 2007;39:908-910.

6. Catassi C., Kryszak D., Louis-Jacques O., Duerksen DR., Hill I., Crowe SE. et al. Detection of Celiac disease in primary care: a multicenter case-finding study in North America. Am J Gastroenterol. 2007;102:1454-1460

7. Lebwohl, B., Ludvigsson, J.F., & Green, P.H.R. The unfolding story of celiac disease risk factors. Clin Gastroenterol Hepatol. 2014; 12(4): 632-635.

8. Catassi C., Kryszak, D., Bhatti, B., Sturgeon, C., Helzlsouer, K., Clipp, S.L., Fasano A. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med. 2010; 42(7): 530-538.

9. Allen PJ. Gluten-Related Disorders: Celiac Disease, Gluten Allergy, Non-Celiac Gluten Sensitivity. Pediatr Nurs. 2015;41(3):146-50.

10. Troncone, R., & Discepolo, V..Celiac disease and autoimmunity. J Pediatr Gastroenterol Nutr.2014; 59(Suppl. 1):S9-S11

11. Tack G.J., Verbeek W.H.M., Schreurs M.W.J., & Mulder C.J.J. The spectrum of celiac disease: Epidemiology, clinical aspects and treatment. Nat Rev Gastroenterol Hepatol. 2010; 7(4): 204-213.

12. Rosén A., Sandström O., Carlsson A., Högberg L., Olén O., Stenlund H., & Ivarsson A. Usefulness of symptoms to screen for celiac disease. Pediatrics. 2014;133(2): 211-218.

13. Kaukinen K., Lindfors K., Collin P., Koskinen O., Mäki M.. Coeliac disease-a diagnostic and therapeutic challenge. Clin Chem Lab Med. 2010 ;48(9):1205-16.

14. Leffler DA, Schuppan D. Update on serologic testing in celiac disease. Am J Gastroenterol. 2010;105(12):2520-4

15. Husby S., Koletzko S., Korponay-Szabó I.R., Mearin M.L., Phillips A., Shamir R., Zimmer K.P.. European society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. RPIA. 2012;20(3): 227-228.

16. Amarri S., Alvisi P., De Giorgio R., Gelli MC., Cicola R., Tovoli F., Sassatelli R., Caio G., Volta U.. Antibodies to deamidated gliadin peptides: an accurate predictor of coeliac disease in infancy. J Clin Immunol. 2013;33(5):1027-30.

17. Zevit N., Shamir R.. Diagnosis of celiac disease: where are we heading after the ESPGHAN 2012 guidelines?. J Pediatr Gastroenterol Nutr. 2014;59 Suppl 1:S13-5.

18. Volta U., Villanacci V.. Celiac disease: diagnostic criteria in progress. Cell Mol Immunol. 2011;8(2):96-102.

19. Hill I.D., Dirks M.H., Liptak G.S., Colletti R.B., Fasano A., Guandalini S., Seidman, E.G.. Guideline for the diagnosis and treatment of celiac disease in children: Recom mendations of the North American society for pediatric gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr. 2005; 40(1): 1-19.

20. Husby S., Koletzko S., Korponay-Szabó IR., Mearin ML., Phillips A., Shamir R., et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54(1):136-60.

21. Guandalini S., & Vallee P.A.. Pediatric celiac disease. 2010. Retrieved from http://emedicine.medscape.com/article/932104overview

22. Elli L., Branchi F., Tomba C., Villalta D., Norsa L., Ferretti F., Roncoroni L., Bardella MT.. Diagnosis of gluten related disorders: Celiac disease, wheat allergy and non-celiac gluten sensitivity. World J Gastroenterol. 2015 ;21(23):7110-9.

23. Vierk KA., Koehler KM., Fein SB., Street DA.. Prevalence of selfreported food allergy in American adults and use of food labels. J Allergy Clin Immunol. 2007;119(6):1504-10.

24. Matricardi PM., Bockelbrink A., Beyer K., Keil T., Niggemann B., Grüber C., Wahn U., Lau S.. Primary versus secondary immunoglobulin E sensitization to soy and wheat in the MultiCentre Allergy Study cohort. Clin Exp Allergy. 2008;38(3):493-500.

25. Ramesh S. Food allergy overview in children. Clin Rev Allergy Immunol. 2008;34(2):217-30

26. Keet CA., Matsui EC., Dhillon G., Lenehan P., Paterakis M., Wood RA. The natural history of wheat allergy. Ann Allergy Asthma Immunol 2009;102(5):410-5. doi:

27. Catassi C., Elli L., Bonaz B., Bouma G., Carroccio A., Castillejo G., et al. Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Experts' Criteria. Nutrients. 2015;7(6):4966-77.

28. Cooper BT., Holmes GK., Ferguson R., Thompson RA., Allan RN., Cooke WT. Gluten-sensitive diarrhea without evidence of celiac disease. Gastroenterology. 1980; 79: 801-806

29. Digiacomo, D.V., Tennyson, C.A., Green, P.H., & Demmer, R.T. Prevalence of gluten-free diet adherence among individuals without celiac disease in the USA: Results from the continuous national health and nutrition examination survey 2009-2010. Scand J Gastroenterol. 2013; 48(8):921-925.

30. Aziz I., Lewis N.R., Hadjivassiliou M., Winfield S.N., Rugg N., Kelsall A., Nevrick L., Sanders D.S. A UK study assessing the population prevalence of self-reported gluten sensitivity and referral characteristics to secondary care. Eur J Gastroenterol Hepatol . 2014; 26(1): 33-39.

31. Volta U., Bardella MT., Calabrò A., Troncone R., Corazza GR.. Study Group for Non-Celiac Gluten Sensitivity. An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity. BMC Med. 2014;12:85.

32. Biesiekierski J.R., Peters S.L., Newnham E.D., Rosella O., Muir J.G., & Gibson P.R. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology. 2013; 145(2): 320-328.e1-3.

33. Vazquez-Roque M., Oxentenko AS. Nonceliac Gluten Sensitivity. Mayo Clin. Proc.. 2015; 90(9):1272-7.

34. Lundin K.E.A., & Alaedini A.. Non-celiac gluten sensitivity. Gastrointestinal Gastrointest Endosc Clin N Am. 2012;22(4):723-34.

35. Catassi. C., Bai J.C., Bonaz B., Bouma G., Calabrò A., Carroccio A., Fasano A. Non-celiac gluten sensitivity: The new frontier of gluten related disorders. Nutrients. 2013; 5(10), 3839-3853.

36. Newton KP., Singer SA. Celiac disease in children and adolescents: special considerations. Semin Immunopathol. 2012;34(4):479-96.

37. Kalaydjian AE., Eaton W., Cascella N., Fasano A. The gluten connection: The association between schizophrenia and celiac disease. Acta Psychiatr Scand. 2006; 113:82-90.

38. Graff H., Handford A. Celiac syndrome in the case histories of five schizophrenics. Psychiatr Q. 1961; 35:306-313.

39. Dohan FC., Grasberger JC., Lowell FM., Johnston HT Jr, Arbegast AW. Relapsed schizophrenics: More rapid improvement on a milk- and cereal-free diet. Br J Psychiatry. 1969; 115:595-596.

40. Dohan FC., Grasberger JC. Relapsed schizophrenics: Earlier discharge from the hospital after cereal-free, milk-free diet. Am J Psychiatry. 1973; 130:685-688.

41. De Santis A., Addolorato G., Romito A., Caputo S., Giordano A., Gambassi G., Taranto C., Manna R., Gasbarrini G. Schizophrenic symptoms and SPECT abnormalities in a coeliac patient: regression after a gluten-free diet. J Intern Med. 1997;242(5):421-3.

42. Cascella NG., Kryszak D., Bhatti B., Gregory P., Kelly DL., Mc Evoy JP., et al. Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population. Schizophr Bull. 2011; 37:94-100.

43. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Leister F. et al. Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia. Biol Psychiatry 2010; 68: 100- 104.

44. Samaroo D., Dickerson F., Kasarda DD., Green PH., Briani C., Yolken RH., et al. Novel immune response to gluten in individuals with schizophrenia. Schizophr Res. 2010; 118:248-255.

45. Söderholm J.D., and Perdue M.H. II.Stress and intestinal barrier function. Am J Physiol. Gastrointest Liver Physiol. 2001; 280:G7-G13.

46. Collins SM., Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology. 2009;136(6):2003-14.

47. Lambert GP. Stress-induced gastrointestinal barrier dysfunction and its inflammatory effects. J Anim Sci. 2009;87(14 Suppl):E101-8.

48. Jong A, Huang SH. Blood-brain barrier drug discovery for central nervous system infections. Curr Drug Targets Infect Disord. 2005;5(1):65-72.

49. Laterra J., Keep R., Betz LA., and Goldstein GW. Blood- Cerebrospinal Fluid Barrier In Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th edition. Siegel GJ, Agranoff BW, Albers RW, editors. Philadelphia: Lippincott-Raven; 1999.

50. Clemente MG., De Virgiliis S., Kang JS., Macatagney R., Musu MP., Di Pierro MR., Drago S., Congia M., Fasano A. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut. 2003;52(2):218-23.

51. Thomas KE., Sapone A., Fasano A., Vogel SN. Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in Celiac disease. J Immunol. 2006 ;176(4):2512-21.

52. Lammers KM., Lu R., Brownley J., Lu B., Gerard C., Thomas K., Rallabhandi P., Shea-Donohue T., Tamiz A., Alkan S., Netzel-Arnett S., Antalis T., Vogel SN., Fasano A. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. 2008;135(1):194-204.e3.

53. Tripathi A., Lammers KM., Goldblum S., Shea-Donohue T., Netzel- Arnett S., Buzza MS., Antalis TM., Vogel SN., Zhao A., Yang S., Arrietta MC., Meddings JB., Fasano A. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA. 2009;106(39):16799-804. doi:

54. Buscaino V. Patologia extraneurale della schizofrenia. Fegato, tubo digerente, sistema reticolo endoteliale. Acta Neurol. 1953; 8: 1-60.

55. Hemmings G. Schizophrenia. Lancet 2004; 364(9442): 1312-1313.

56. Severance EG., Gressitt KL., Stallings CR., Origoni AE., Khushalani S., Leweke FM. et al. Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr. Res. 2013; 148(1-3): 130-137.

57. Mortensen PB., Nørgaard-Pedersen B., Waltoft BL., Sørensen TL., Hougaard D., Yolken RH. Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophr Bull. 2007;33(3):741-4.

58. Torrey EF., Bartko JJ., Lun ZR., Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: a metaanalysis. Schizophr Bull. 2007;33(3):729-36.

59. Yolken RH., Dickerson FB., Fuller Torrey E. Toxoplasma and schizophrenia. Parasite Immunol. 2009;31(11):706-15. doi:

60. Severance EG., Kannan G., Gressitt KL., Xiao J., Alaedini A., Pletnikov MV., Yolken RH. Anti-gluten immune response following Toxoplasma gondii infection in mice. PLoS One. 2012;7(11):e50991

61. Nemani K et al.. Schizophrenia and the gut-brain axis. Prog Neuro-Psychoph. 2015; 56:155-166.

62. Hornig M, The role of microbes and autoimmynity in the pathogenesis of neuropsychiatric illness. Curr. Opin. Rheumatol. 2013; 25(4): 488-795.

63. Cryan JF., Dinan TG.. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13(10):701-12.

64. Caminero A., Herrán AR., Nistal E., Pérez-Andrés J., Vaquero L., Vivas S. et al. .Diversity of the cultivable human gut microbiome involved in gluten metabolism: isolation of microorganisms with potential interest for coeliac disease. EMS Microbiol Ecol. 2014;88(2):309-19.

65. Hong S.N. and Rhee P. L. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J. Gastroenterol. 2014; 20: 2470-2481.

66. Kau AL., Ahern PP., Griffin NW., Goodman AL., Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature. 2011;474(7351):327-36. .

67. David LA., Maurice CF., Carmody RN., Gootenberg DB., Button JE., Wolfe BE et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014 23;505(7484):559-63.

68. Brown K., DeCoffe D., Molcan E., Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients 2012; 4: 1095-1119

69. Severance E.G., Prandovszky E., Castiglione J., Yolken R.H. Gastroenterology issues in schizophrenia: why the gut matters Curr Psychiatry Rep. 2015; 17(5): 27

70. Kostic A.D., Xavier R.J., Gevers D. The Microbiome in Inflammatory Bowel Diseases: Current Status and the Future Ahead. Gastroenterology. 2014 ; 146(6): 1489-1499.

71. Gevers D., Kugathasan S., Denson LA., Vázquez-Baeza Y., Van Treuren W., Ren B., Schwager E. et al. The treatment-naïve microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;12: 15(3): 382-392.

72. Diaz Heijtz R., Wang S., Anuar F., Qian Y., Björkholm B., Samuelsson A., Hibberd ML., Forssberg H., Pettersson S. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A. 2011;108(7):3047-52.

73. Clarke G1, Grenham S., Scully P., Fitzgerald P., Moloney RD., Shanahan F., Dinan TG, Cryan JF. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry. 2013;18(6):666-73.

74. Sudo N., Chida Y., Aiba Y., Sonoda J., Oyama N., Yu XN. et al.. Postnatal microbial colonization programs the hypothalamicpituitary- adrenal system for stress response in mice. J. Physiol. 2004; 558: 263-275.

75. Dickerson FB., Stallings C., Origoni A., Katsafanas E. et al. Effect of Probiotic Supplementation on Schizophrenia Symptoms and Association With Gastrointestinal Functioning: A Randomized, Placebo-Controlled Trial Prim Care Companion CNS Disord. 2014; 16(1): pii: PCC.13m01579. doi:

76. Severance EG., Dickerson FB., Halling M., Krivogorsky B., Haile L., Yang S. et al. Subunit and whole molecule specificity of the antibovine casein immune response in recent onset psychosis and schizophrenia. Schizophr Res. 2010;118(1-3):240-7.

77. Fernandez-Feo M., Wei G., Blumenkranz G., Dewhirst FE., Schuppan D., Oppenheim FG. et al. The cultivable human oral gluten-degrading microbiome and its potential implications in coeliac disease and gluten sensitivity. Clin Microbiol Infect. 2013 ;19(9):E386-94.

78. Zioudrou C., Streaty R.A., Klee W.A. Opioid peptides derived from foodproteins.Theexorphins.J.Biol.Chem. 1979;254:2446-2449.

79. Teschemacher H. Opioid receptor ligands derived from food proteins. Curr.Pharm.Des. 2003; 9:1331-1344.

80. Bressan P., Kramer P.. Bread and Other Edible Agents of Mental Disease. Front Hum Neurosci. 2016;10:130.

81. Margules D.L. β-endorphinandendoloxone: hormonesoftheautonomic nervous system for the conservation or expenditure of bodily resources and energy inanticipation off amineorfeast. ActaDiabetol. 1979; 3:155-162.

82. Margules D. L. ‘‘Energy balance and opioid receptors: epsilons in the periphery promote conservation; κ and δ in the CNS permit expenditures,’’ in The Eating Disorders: Medical and Psychological Bases of Diagnosis and Treatment, eds B.J. Blinder ,B.F. Chaitinand R.S. Goldstein.New York, NY: PMA Publishing. 1988;21-27.

83. Yeomans M. R., and Gray R. W. Opioid peptides and the control of human ingestive behaviour. Neurosci. Biobehav. Rev. 2002;26:713-728.

84. Kostyra E., Sienkiewicz-Szlapka E., Jarmolowska B., Krawczuk S., and Kostyra H.. Opioid peptides derived from milk proteins. Pol. J. Food Nutr. Sci. 2004; 13:25-35.

85. Miner-Williams W. M., Stevens B. R., and Moughan P. J..Are intact peptides absorbed from the healthy gut in the adult human? Nutr. Res. Rev. 2014;27:308-329.

86. Ulluwishewa D., Anderson R. C., McNabb W. C., Moughan P. J., Wells J. M., and Roy N. C. Regulation of tight junction permeability by intestinal bacteria and dietary components. J. Nutr. 2011;141:769-776.

87. Purohit V., Bode J.C., Bode C., Brenner D.A., Choudhry M.A., Hamilton F., et al. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin and medical consequences: summary of a symposium. Alcohol. 2008; 42:349-361.

88. Smale S., and Bjarnason I. Determining small bowel integrity following drug treatment. Br. J. Clin. Pharmacol. 2003; 56:284-291.

89. Hemmings W.A. The entry into the brain of large molecules derived from diet ary protein.Proc.R.Soc.Lond.B.Biol.Sci. 1978;200:175-192.

90. Sun Z., and Cade J. R. A peptide found in schizophrenia and autism causes behavioral changes in rats. Autism. 1999; 3:85-95.

91. Meisel H., and FitzGerald R. J. Opioid peptides encrypted in intact milk protein sequences. Br. J. Nutr. 2000;84:S27-S31.

92. Hole K., Bergslien H., Jørgensen H. A., Berge O. G., Reichelt K. L., and Trygstad O. E. A peptide-containing fraction in the urine of schizophrenic patients which stimulates opiate receptors and inhibits dopamine uptake. Neuroscience 1979; 4: 1883-1893.

93. Drysdale A., Deacon R., Lewis P., Olley J., Electricwala A., and Sherwood R. A peptide-containing fraction of plasma from schizophrenic patients which binds to opiate receptors and induces hyper-reactivity in rats. Neuroscience. 1982;7:1567-1573.

94. Sokolov O., Kost N., Andreeva O., Korneeva E., Meshavkin V., Tarakanova Y., et al. Autistic children display elevated urine levels of bovine casomorphin-7 immunoreactivity. Peptides. 2014;56: 68-71.

95. Cass H., Gringras P., March J., McKendrick I., O’Hare A. E., Owen L., et al. Absence of urinary opioidpeptides In children with autism. Arch.Dis. Child. 2008;93:745-750.

96. Sun Z., Cade J. R., Fregly M. J., and Privette R. M. βCasomorphin induces Fos-like immunoreactivity in discrete brain regions relevant to schizophrenia and autism. Autism 1999; 3: 67-83.

97. Cade R., Privette M., Fregly M., Rowland N., Sun Z. J., Zele V., et al. Autism and schizophrenia: intestinal disorders. Nutr. Neurosci. 2000;3: 57-72.

98. Genuis S.J., and Lobo R. A. Gluten sensitivity presenting as a neuropsychiatric disorder. Gastroenterol. Res. Pract. 2014:ID 293206. http://dx.doi.org/10.1155/2014/293206

99. Lister J., Fletcher P. J., Nobrega J. N., and Remington G. Behavioral effects of food-derived opioid-like peptides in rodents: implications for schizophrenia? Pharmacol Biochem Behav. 2015;134:70-8.

100. Emrich HM., Cording C., Pirée S., Kölling A., von Zerssen D., Herz A. Indication of an antipsychotic action of the opiate antagonist naloxone. Pharmakopsychiatr Neuropsychopharmakol. 1977;10(5):265-70

101. Gillberg C., Terenius L., and Lönnerholm G. Endorphin activity in childhood psychosis. Spinal fluid levels in 24 cases. Arch. Gen. Psychiatry. 1985:42:780-783.

102. Lindström L. H., Besev G., Gunne L. M., and Terenius L. CSF levels of receptor-active endorphins in schizophrenic patients: correlations with symptomatology and monoamine metabolites. Psychiatry Res. 1986; 19: 93-100.

103. Lindström LH., Nyberg F., Terenius L., Bauer K., Besev G., Gunne LM., Lyrenäs S., Willdeck-Lund G., Lindberg B. CSF and plasma beta- casomorphin-like opioid peptides in postpartum psychosis. Am J Psychiatry. 1984;141(9):1059-66

104. Severance EG., Gressitt KL., Alaedini A., Rohleder C., Enning F., Bumb JM., Müller JK., Schwarz E., Yolken RH., Leweke FM. IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia. Brain Behav Immun. 2015;44:148-58.

105. Newton KP., Singer SA. Celiac disease in children and adolescents: special considerations. Semin Immunopathol. 2012;34(4):479-96.

106. Food and Drug Administration, HHS. Food labeling: gluten-free labeling of foods. Final rule. Fed Regist. 2013 Aug 5;78(150):47154-79.

107. Potkin SG., Weinberger D., Kleinman J., Nasrallah H., Luchins D., Bigelow L., Linnoila M., Fischer SH., Bjornsson TD., Carman J., Gillin JC., Wyatt RJ.: Wheat gluten challenge in schizophrenic patients. Am J Psychiatry 1981; 138(1208):11.

108. Arroll MA., Wilder L., Neil J.. Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. Nutr J. 2014 ; 16:13:91

109. Jackson J., Eaton W., Cascella N., Fasano A., Warfel D., Feldman S., Richardson C., Vyas G., Linthicum J., Santora D., Warren KR., Carpenter WT. Jr, Kelly DL.. A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies. Schizophr Res. 2012;140(1-3):262-3.

110. Lurie Y., Landau DA., Pfeffer J., Oren R. Celiac disease diagnosed in the elderly. J Clin Gastroenterol. 2008 ;42(1):59-61.

111. De Santis A., Addolorato G., Romito A., Caputo S., Giordano A., Gambassi G., et al. Schizophrenic symptoms and SPECT abnormalities in a coeliac patient: Regression after a gluten-free diet. Journal of Internal Medicine. 1997; 242:421-423.

112. Eaton WW., Chen LY., Dohan FC. Jr, Kelly DL., Cascella N. Improvement in psychotic symptoms after a gluten-free diet in a boy with complex autoimmune illness. Am J Psychiatry. 2015;172(3):219-21.

113. Lionetti E., Leonardi S., Franzonello C., Mancardi M., Ruggieri M., Catassi C. Gluten Psychosis: Confirmation of a New Clinical Entity. Nutrients. 2015;7(7):5532-9.

114. Hollon J.R., Cureton P.A., Martin M.L., Puppa E.L.L., & Fasano A. Trace gluten contamination may play a role in mucosal and clinical recovery in a subgroup of diet-adherent non-responsive celiac disease patients. BMC Gastroenterology. 2013;13(1).

115. Dewar DH., Donnelly SC., McLaughlin SD., Johnson MW., Ellis HJ., Ciclitira PJ. Celiac disease: management of persistent symptoms in patients on a gluten-free diet. World J Gastroenterol. 2012;18(12):1348-56.

116. Mukherjee R., Kelly CP., Schuppan D. Nondietary therapies for celiac disease. Gastrointest Endosc Clin N Am. 2012;22(4):811-31

117. Stoven S., Murray JA., Marietta E. Celiac disease: advances in treatment via gluten modification. Clin Gastroenterol Hepatol. 2012;10(8):859-62

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 299 299 39
PDF Downloads 126 126 26